4th Nov 2014 09:17
LONDON (Alliance News) - Vectura Group PLC on Tuesday said its partner Sandoz has been given marketing authorisation by pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania for the AirFluSal Forspiro, an inhaler for patients suffering from asthma or chronic obstructive pulmonary disease.
Vectura originally developed the product before licensing it to Sandoz, the generics arm of Swiss drugs company Novartis International AG, in 2006.
The latest authorisations brings the total number of countries to have approved the inhaler to 15. It has been launched in five countries so far.
Vectura shares were trading flat at 116.75 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L